Indica Labs Announces Webinar For Late November
Indica Labs: Learn how to implement Lung PD-L1 AI to assist PD-L1 scoring in non-small cell lung cancer.
Lung PD-L1 AI: Development and Validation of an Automated PD-L1 Tumor Proportion Scoring Algorithm in Non-Small Cell Lung Cancer
Date: 30 November 2023
Time: 8:00 – 9:00 PST | 11:00 – 12:00 EST | 16:00 – 17:00 GMT
Location: Webinar
Summary
Manual tumor proportion scoring of PD-L1 expression is the current gold standard for clinical reporting in non-small cell lung cancer (NSCLC) cases. However, scoring challenges include the existence of multiple PD-L1 assays, intra-tumor heterogeneity and inter-observer variability which may lead to variability in PD-L1 scoring and suboptimal treatment decisions.
Join Indica Labs in this 1-hour webinar to learn about the development and validation of Lung PD-L1 AI, an automated PD-L1 Tumor Proportion Scoring algorithm for NSCLC samples. The webinar will also include a demonstration of how the algorithm seamlessly integrates into the HALO AP® diagnostic digital pathology platform to assist scoring PD-L1 in NSCLC cases.
Learning Objectives
- Understand the current challenges with PD-L1 scoring in NSCLC
- Learn how Lung PD-L1 AI was developed and validated
- Learn how to deploy Lung PD-L1 AI in HALO AP to support PD-L1 scoring and increase scoring consistency
Presenters
Dr. David Dorward
Consultant Thoracic Pathologist
Royal Infirmary of Edinburgh
Dr. David Dorward is a Consultant Pathologist who specializes in the diagnosis and molecular profiling of lung cancer. His research has predominantly focused on understanding lung inflammation in response to infection, injury and cancer but he also has a growing interest in the application of digital pathology in clinical practice. As well as exploring the opportunities provided by integrating digital reporting into routine histopathology practice, David has been collaborating with Indica on the development of a number of AI tools. He is currently Digital Pathology lead for both NHS Lothian and the Scottish Pathology Network (SPAN).
Daniela Rodrigues
Imaging Scientist, AI Diagnostics
Indica Labs
Meredith Lodge has a background in neuroscience, receiving her PhD in Neurophysiology from the University of Basel, Switzerland. Her thesis evaluated the excitatory and inhibitory synaptic connections of adult-born young granule cells in the hippocampus, using electrophysiology, IHC and image analysis. Following her PhD, Meredith joined OracleBio, where she supported and managed image analysis studies for pharmaceutical and biotechnology clients using HALO and HALO AI software. Meredith joined the AI Diagnosticsteam at Indica Labs in 2022, where she manages the development of AI-based clinical products.
SOURCE: Indica Labs
